Quick Answer
Raphael Pharmaceutical Inc. reported Cash and Equivalents of $19.0 thousand for fiscal year 2024.
Raphael Pharmaceutical Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $19.0K | -91.7% |
| 2023 | $230.0K | -20.1% |
| 2022 | $288.0K | +88.2% |
| 2021 | $153.0K | +61.1% |
| 2020 | $95.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $20.0K | -83.3% | -60.0% |
| March 31, 2025 | $50.0K | -82.6% | +163.2% |
| December 31, 2024 | $19.0K | -91.7% | -52.5% |
| September 30, 2024 | $40.0K | -86.6% | -66.7% |
| June 30, 2024 | $120.0K | +8.1% | -58.2% |
| March 31, 2024 | $287.0K | +655.3% | +24.8% |
| December 31, 2023 | $230.0K | -20.1% | -23.1% |
| September 30, 2023 | $299.0K | +221.5% | +169.4% |
- Raphael Pharmaceutical Inc. showed a decrease of -91.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2024 period, Raphael Pharmaceutical Inc.’s cash and equivalents has declined by 80.0% (from $95.0 thousand to $19.0 thousand).
- The most recent figure is from Raphael Pharmaceutical Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: